UY33317A - Nuevos derivados de pirazol - Google Patents
Nuevos derivados de pirazolInfo
- Publication number
- UY33317A UY33317A UY0001033317A UY33317A UY33317A UY 33317 A UY33317 A UY 33317A UY 0001033317 A UY0001033317 A UY 0001033317A UY 33317 A UY33317 A UY 33317A UY 33317 A UY33317 A UY 33317A
- Authority
- UY
- Uruguay
- Prior art keywords
- pirazol
- new derivatives
- sphingosine
- agonists
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
La presente invención se refiere a un compuesto de fórmula (I), al procedimiento para preparar dichos compuestos y a su uso en el tratamiento de una condición patológica o enfermedad susceptible de mejorar por agonistas de los receptores de 1-fosfato de esfingosina (S1P1).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10382128A EP2390252A1 (en) | 2010-05-19 | 2010-05-19 | New pyrazole derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
UY33317A true UY33317A (es) | 2011-10-31 |
Family
ID=42664897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001033317A UY33317A (es) | 2010-05-19 | 2011-04-06 | Nuevos derivados de pirazol |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2390252A1 (es) |
TW (1) | TW201141858A (es) |
UY (1) | UY33317A (es) |
WO (1) | WO2011144338A1 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2348023B9 (en) | 2005-12-13 | 2017-03-08 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
CN101932582B (zh) | 2007-06-13 | 2013-09-25 | 因塞特公司 | 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐 |
SG176111A1 (en) | 2009-05-22 | 2011-12-29 | Incyte Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
CN102458581B (zh) | 2009-05-22 | 2016-03-30 | 因塞特控股公司 | 作为JANUS激酶抑制剂的吡唑-4-基-吡咯并[2,3-d]嘧啶和吡咯-3-基-吡咯并[2,3-d]嘧啶的N-(杂)芳基-吡咯烷衍生物 |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
ME02386B (me) | 2010-03-10 | 2016-09-20 | Incyte Holdings Corp | Derivati piperidin-4-il azetidina kao inhibitori jak1 |
KR102303885B1 (ko) | 2010-05-21 | 2021-09-24 | 인사이트 홀딩스 코포레이션 | Jak 저해제에 대한 국소 제형 |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
EP2640723A1 (en) | 2010-11-19 | 2013-09-25 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
EA201590930A1 (ru) | 2012-11-15 | 2015-08-31 | Инсайт Корпорейшн | Лекарственные формы руксолитиниба с замедленным высвобождением |
WO2014127149A1 (en) * | 2013-02-15 | 2014-08-21 | Allergan, Inc. | Substituted 4,5-dihydropyrazole-1,2,4-oxadiazole derivatives as sphingosine receptor modulators |
US20140235588A1 (en) * | 2013-02-15 | 2014-08-21 | Allergan, Inc. | Substituted 1h-pyrazol-1,2,4-oxadiazole derivatives as sphingosine receptor modulators |
KR101939657B1 (ko) * | 2013-02-20 | 2019-01-17 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제, 그의 제조방법 및 그를 활성성분으로서 함유하는 약제학적 조성물 |
JP6397831B2 (ja) | 2013-03-06 | 2018-09-26 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤の製造方法及びその中間体 |
MY195091A (en) | 2013-08-07 | 2023-01-10 | Incyte Corp | Sustained Release Dosage Forms for a JAK1 Inhibitor |
RU2016132324A (ru) * | 2014-01-21 | 2018-03-01 | Ф. Хоффманн-Ля Рош Аг | Имидазолы для лечения и профилактики респираторной синцитиальной вирусной инфекции |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
KR20180036415A (ko) | 2016-09-30 | 2018-04-09 | 재단법인 한국파스퇴르연구소 | 신규 헤테로아릴 화합물, 이의 거울상 이성질체, 부분 입체 이성질체 또는 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 항바이러스용 조성물 |
WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
CR20200379A (es) | 2018-01-30 | 2021-03-05 | Incyte Corp | Procesos e intermedio para elaborar un inhibidor de jak campo técnico |
CA3095487A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Treatment of hidradenitis suppurativa using jak inhibitors |
AR117169A1 (es) | 2018-11-28 | 2021-07-14 | Bayer Ag | (tio)amidas de piridazina como compuestos fungicidas |
EP4146628A1 (en) | 2020-05-06 | 2023-03-15 | Bayer Aktiengesellschaft | Pyridine (thio)amides as fungicidal compounds |
EP4149929A1 (en) | 2020-05-12 | 2023-03-22 | Bayer Aktiengesellschaft | Triazine and pyrimidine (thio)amides as fungicidal compounds |
US20230192617A1 (en) | 2020-05-19 | 2023-06-22 | Bayer Cropscience Aktiengesellschaft | Azabicyclic(thio)amides as fungicidal compounds |
JP2023527036A (ja) | 2020-05-27 | 2023-06-26 | バイエル、アクチエンゲゼルシャフト | 活性化合物の組合せ物 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
TW202220651A (zh) * | 2020-09-28 | 2022-06-01 | 南韓商Lg化學股份有限公司 | 神經鞘胺醇-1-磷酸受體促效劑的用途 |
WO2022065939A1 (ko) * | 2020-09-28 | 2022-03-31 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제의 용도 |
WO2022080812A1 (ko) * | 2020-10-13 | 2022-04-21 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조 방법 |
KR20220142377A (ko) * | 2021-04-14 | 2022-10-21 | 주식회사 엘지화학 | 입도가 조절된 스핑고신-1-인산 수용체 효능제를 포함하는 약제학적 조성물 |
CN117120038A (zh) * | 2021-04-14 | 2023-11-24 | 株式会社Lg化学 | 包含鞘氨醇-1-磷酸受体激动剂的固体制剂的制备方法 |
WO2022220596A1 (ko) * | 2021-04-14 | 2022-10-20 | 주식회사 엘지화학 | 습식과립법에 의한 스핑고신-1-인산 수용체 효능제를 포함하는 경구용 고형 제제의 제조 방법 |
KR20220142376A (ko) * | 2021-04-14 | 2022-10-21 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제를 포함하는 직접 타정용 약제학적 조성물 |
WO2023078915A1 (en) | 2021-11-03 | 2023-05-11 | Bayer Aktiengesellschaft | Bis(hetero)aryl thioether (thio)amides as fungicidal compounds |
WO2024068950A1 (en) | 2022-09-30 | 2024-04-04 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
WO2024068947A1 (en) | 2022-09-30 | 2024-04-04 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2303792A (en) | 1992-06-23 | 1994-01-24 | Motorola, Inc. | Multi-modulation scheme compatible radio |
NZ502870A (en) | 1995-06-21 | 2001-06-29 | Asta Medica Ag | Inhaler for powdered medicaments comprising a visual display device to indicate the discharge status of the inhaler |
DE10129703A1 (de) | 2001-06-22 | 2003-01-02 | Sofotec Gmbh & Co Kg | Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren |
DE10202940A1 (de) | 2002-01-24 | 2003-07-31 | Sofotec Gmbh & Co Kg | Patrone für einen Pulverinhalator |
DE60324416D1 (de) | 2002-05-16 | 2008-12-11 | Novartis Ag | Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie |
GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
EP1484057A1 (en) | 2003-06-06 | 2004-12-08 | Aventis Pharma Deutschland GmbH | Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain |
WO2005025553A2 (en) | 2003-09-12 | 2005-03-24 | Neuronova Ab | Treatment of disorders of nervous systemsystem with fty720 |
GB0329498D0 (en) | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
CA2572790C (en) | 2004-07-16 | 2014-12-23 | Laboratorios Almirall, S.A. | Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler |
CN101378741A (zh) | 2006-01-27 | 2009-03-04 | 弗吉尼亚大学专利基金会 | 治疗神经性疼痛的方法 |
TWI389683B (zh) | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
US8318812B2 (en) | 2006-06-02 | 2012-11-27 | The Ohio State University Research Foundation | Therapeutic agents for the treatment of lymphoid malignancies |
GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
EP2392320A1 (en) | 2006-08-17 | 2011-12-07 | University Of Chicago | Treatment of inflammatory diseases |
NZ577111A (en) * | 2006-12-15 | 2012-05-25 | Abbott Lab | Novel oxadiazole compounds |
JP5702138B2 (ja) * | 2007-05-18 | 2015-04-15 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 過剰増殖障害および血管新生に関連する疾患の処置に有用なヘテロアリール置換ピラゾール誘導体 |
SI2291080T1 (sl) * | 2008-05-14 | 2015-11-30 | The Scripps Research Institute | Novi modulatorji sfingosinskih fosfatnih receptorjev |
-
2010
- 2010-05-19 EP EP10382128A patent/EP2390252A1/en not_active Withdrawn
-
2011
- 2011-04-06 UY UY0001033317A patent/UY33317A/es not_active Application Discontinuation
- 2011-04-19 TW TW100113565A patent/TW201141858A/zh unknown
- 2011-05-18 WO PCT/EP2011/002487 patent/WO2011144338A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
TW201141858A (en) | 2011-12-01 |
WO2011144338A1 (en) | 2011-11-24 |
EP2390252A1 (en) | 2011-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY33317A (es) | Nuevos derivados de pirazol | |
UY32296A (es) | Nuevos compuestos | |
CL2016001732A1 (es) | Métodos sintéticos para compuestos espiro-oxoindol (div. sol. 3633-13). | |
UY33353A (es) | Compuestos adecuados para el tratamiento de trastornos metabolicos y metodos de preparacion | |
CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
CU20110052A7 (es) | Compuestos orgánicos | |
UY32292A (es) | Agonistas de s1p1 y métodos de preparación y uso | |
CR20120264A (es) | Compuestos | |
ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
UY33587A (es) | Nuevos compuestos como inhibidores de quinasas syk y jak | |
BR112014002922A2 (pt) | compostos da fórmula i, processo de preparação de compostos da fórmula i, compostos da formula xii, viii e xi, composições agroquímicas, uso e semente | |
ECSP13012611A (es) | Derivados de pirazol-aminopirimidina como moduladores de la lrrk2 | |
UY35683A (es) | Polimorfo de inhibidores de tirosina quinasa de bazo (syk) | |
CO6771439A2 (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
DOP2009000237A (es) | Derivados de indazol oxadiazol sustituidos para uso como agonistas esfingosina 1-fosfato (s1p) | |
ECSP12012221A (es) | Anticuerpos anti-cd40 | |
ECSP13012596A (es) | Proceso de elaboración para derivados de pirimidina | |
BR112014003216A2 (pt) | compostos, processos para preparação de compostos de fórmula i, composições agroquímicas, uso de compostos de fórmula i ou viii e uso de pelo menos um composto de fórmula i ou viii | |
BR112015004029A2 (pt) | Processo para preparação de teneligliptina, de um composto ou de sal ou hidrato do mesmo | |
CR20150245A (es) | Proceso novedoso para la elaboración de compuestos para uso en el tratamiento de cáncer | |
CL2012002082A1 (es) | Proceso para la preparacion de lacosamida, por hidroximetilación; compuestos intermediarios. | |
BR112014031091A2 (pt) | Derivados de piperidina para agonista de gpr119 | |
CO7350641A2 (es) | Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados | |
BR112014001539A2 (pt) | processo para obter uma composição contendo fatores de crescimento de um composto do sangue, e composição obtida pelo dito processo | |
CR20160016A (es) | Pirazolpiridinas sustituidas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
104 | Application deemed to be withdrawn (no substantive examination fee paid) |
Effective date: 20130802 |